NCT04015908

A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this trial is to determine whether the combination of three non-opioid analgesics (multimodal analgesia) can significantly reduce or eliminate the need for opioids after ambulatory surgery. A secondary objective would be to present credible data for insurance providers about the opioid sparing effect of these medications. This data may encourage insurance providers to support payment for short term use of certain analgesics that currently require prior authorization.

Detailed description

Prescription opioids are associated with addiction and accidental overdose, yet they continue to be the most commonly prescribed analgesics after ambulatory surgery. Multimodal analgesia is a promising alternative to opioids. It is based on the theory that a combination of more than one analgesic (with non-opioid mechanisms of action) can provide pain relief equal to or exceeding that of traditional opioids. Multimodal analgesia is not associated with opioid related side effects such as respiratory depression, nausea, constipation, and itching. Implementation of multi-modal analgesia in an ambulatory setting is challenging for a number of reasons. First, patient compliance with multiple medications and complex dosing schedules is poor. Second, misinformation still exists about the dosing of acetaminophen and NSAIDS (non-steroidal anti-inflammatory drugs). For example, many patients and health care providers believe that acetaminophen and NSAIDS cannot be taken concurrently. As a result, the additive analgesic effect of combining these drugs is not achieved. Finally, some medications used for multimodal analgesia can be difficult to procure in the ambulatory setting. For example, pregabalin (trade name Lyrica) has been used successfully to treat acute pain and reduce opioid requirements after surgery. However, its mechanism of action is similar to that of gabapentin (an older and less expensive drug) and insurers are reluctant to approve its use over the expensive alternative. Although gabapentin is a useful analgesic for chronic pain, its delayed onset of activity and unpredictable blood levels after oral administration make it impractical to use in the setting of acute pain. In fact, optimal dosing of gabapentin may require several days or weeks to establish.By contrast, pregabalin has a rapid onset of action with consistent and predictable plasma levels after oral administration. For this trial, patients in the control group would receive traditional postoperative pain medication consisting of a combination of oxycodone and acetaminophen (trade name Percocet) as needed at 4-6 hour intervals. Patients in the study group would receive the following: * Three non-opioid pain medications (acetaminophen,celecoxib, and pregabalin) would be taken concurrently at six hour intervals for a period of 7 days. * These three non-opioid medications (acetaminophen, celecoxib, and pregabalin ) would be provided in a "blister pack". All scheduled pain medication for a given 6 hour interval would be contained in a single compartment to simplify compliance for the patient. Study patients would also have access to oxycodone as a "rescue medication". The principles of postoperative pain management addressed in this protocol are supported by existing literature. 1. Patient compliance with complex medication dosing protocols may be improved using calender and time based "blister packs". 2. Pain control using combined acetaminophen and NSAID is superior to that either drug in isolation 3. Pregabalin can reduce opioid requirements and opioid related nausea when treating acute pain. The primary objective of this trial is to determine whether the combination of three non-opioid analgesics (multimodal analgesia) can significantly reduce or eliminate the need for opioids after ambulatory surgery. A secondary objective would be to present credible data for insurance providers about the opioid sparing effect of these medications. This data may encourage insurance providers to support payment for short term use of certain analgesics that currently require prior authorization.

Conditions

• Opioid Use

Interventions

Type	Name	Description
DRUG	Celecoxib	Celecoxib 100mg
DRUG	Acetaminophen	Acetaminophen 325mg
DRUG	Pregabalin	Pregabalin 50 mg
DRUG	Oxycodone	oxycodone 5-10 mg
DRUG	Percocet	Percocet (oxycodone 5mg/acetaminophen 325 mg)

Timeline

• Start date: 2019-08-01
• Primary completion: 2023-01-31
• Completion: 2023-01-31
• First posted: 2019-07-11
• Last updated: 2024-07-08
• Results posted: 2024-07-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study